Atrion (NASDAQ:ATRI) Stock Rating Lowered by StockNews.com

StockNews.com lowered shares of Atrion (NASDAQ:ATRI) from a hold rating to a sell rating in a research note published on Wednesday.

Atrion Price Performance

Atrion stock opened at $414.95 on Wednesday. Atrion has a 52-week low of $274.98 and a 52-week high of $613.16. The company has a market cap of $730.31 million, a P/E ratio of 37.62 and a beta of 0.62. The business has a 50-day simple moving average of $412.89 and a two-hundred day simple moving average of $365.53.

Atrion (NASDAQ:ATRI) last posted its quarterly earnings data on Thursday, February 29th. The medical instruments supplier reported $3.65 earnings per share (EPS) for the quarter. Atrion had a net margin of 11.46% and a return on equity of 8.07%. The company had revenue of $43.58 million for the quarter.

Atrion Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, March 29th. Investors of record on Friday, March 15th were issued a $2.20 dividend. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $8.80 dividend on an annualized basis and a yield of 2.12%. Atrion’s dividend payout ratio is currently 79.78%.

Hedge Funds Weigh In On Atrion

Institutional investors and hedge funds have recently bought and sold shares of the stock. Exchange Traded Concepts LLC bought a new position in shares of Atrion in the third quarter worth about $333,000. Bank of New York Mellon Corp raised its stake in Atrion by 2.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 10,006 shares of the medical instruments supplier’s stock worth $4,134,000 after acquiring an additional 194 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Atrion by 2.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 10,385 shares of the medical instruments supplier’s stock valued at $4,291,000 after purchasing an additional 243 shares in the last quarter. WINTON GROUP Ltd bought a new position in shares of Atrion in the third quarter worth approximately $208,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Atrion in the fourth quarter worth $108,000. 66.19% of the stock is currently owned by hedge funds and other institutional investors.

About Atrion

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.